Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

• Status: Completed
• Trial end date: 2008-04-01

Summary

This is a Phase III, multicenter, open-label study, that will evaluate the improvement of nutrient absorption when participants will receive Ultrase® MT20. This study is sponsored by Aptalis (formerly Axcan). This study is performed in children from 7 to 11 years old.

• Phase: Phase 3

Details

• Lead Sponsor: Forest Laboratories
• Treatments: Pancreatin; Pancrelipase